Teva Pharmaceuticals to Pay $450 Million in Settlement Over Kickback Allegations
Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. have agreed to pay $450 million to resolve allegations of kickback schemes and price fixing. The settlement, announced Thursday by the U.S. Department of Justice, addresses violations of the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), marking a major victory in the government's ongoing efforts to combat healthcare fraud.